Ferula gummosa in colorectal cancer: a bioinformatics and experimental validation study

Abbas Alibakhshi , Shima Gharibi, Ali Shojaeian, Atefeh Asgari, Razieh Amini, Mehdi Rahimmalek, Shahrzad Ahangarzadeh , Antoni Szumny

Abstract


Background and purpose: Colorectal cancer (CRC) is a significant global health challenge, necessitating a comprehensive molecular understanding for personalized treatments. Molecular profiling has elucidated key biomarkers that are essential for prognosis, treatment responsiveness, and targeted therapeutic interventions.

Experimental approach: This study explored the role of indigenous phytochemicals, using bioinformatics and experimental assays to identify potential CRC-specific therapeutic targets.

Findings/Results: A system biology and drug-target network analysis identified four proteins (ANG, DPP4, INSR, and MAPK14) as potential targets for further investigation. Molecular docking studies showed that the cauferoside from Ferula gummosa has a strong binding affinity for these proteins. Molecular dynamics simulations confirmed the stability of the compound-protein complexes. In vitro assays demonstrated the cytotoxic effects of F. gummosa extracts on CRC cells. The leaf extract significantly downregulated the expression of the ANG, DPP4, INSR, and MAPK14 genes, while the root extract exhibited differential effects on gene expression.

Conclusion and implications: The findings suggest the potential therapeutic efficacy of F. gummosa against CRC and emphasize the importance of a dual methodology involving bioinformatics and experimental validation in drug discovery. Further in vivo and clinical studies are warranted to validate these findings and facilitate potential therapeutic applications.

 


Keywords


Colorectal cancer; Ferula gummosa; Molecular docking; Molecular dynamics; Phytochemicals; System biology.

Full Text:

PDF

References


Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers (Basel). 2021;13(9):2025,1-23. DOI: 10.3390/cancers13092025.

Alves Martins BA, de Bulhões GF, Cavalcanti IN, Martins MM, de Oliveira PG, Martins AMA. Biomarkers in colorectal cancer: the role of translational proteomics research. Front Oncol. 2019;9:1284,1-11. DOI: 10.3389/fonc.2019.01284.

Bellio H, Fumet JD, Ghiringhelli F. Targeting BRAF and RAS in colorectal cancer. Cancers (Basel). 2021;13(9):2201,1-17. DOI: 10.3390/cancers13092201.

Janani B, Vijayakumar M, Priya K, Kim JH, Prabakaran DS, Shahid M, et al. EGFR-based targeted therapy for colorectal cancer: promises and challenges. Vaccines (Basel). 2022;10(4):499,1-15.DOI: 10.3390/vaccines10040499.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53(7):852-864.DOI: 10.3109/0284186X.2014.895036.

Vacante M, Borzì AM, Basile F, Biondi A. Biomarkers in colorectal cancer: current clinical utility and future perspectives. World J Clin Cases. 2018;6(15):869-881. DOI: 10.12998/wjcc.v6.i15.869.

Mia MAR, Dey D, Sakib MR, Biswas MY, Prottay AAS, Paul N, et al. The efficacy of natural bioactive compounds against prostate cancer: molecular targets and synergistic activities. Phytother Res. 2023;37(12):5724-5754. DOI: 10.1002/ptr.8017.

Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48,1-20.DOI: 10.1186/s12943-018-0804-2.

Alibakhshi A, Malekzadeh R, Hosseini SA, Yaghoobi H. Investigation of the therapeutic role of native plant compounds against colorectal cancer based on system biology and virtual screening. Sci Rep. 2023;13(1):11451,1-13. DOI: 10.1038/s41598-023-38134-5.

Kubczak M, Szustka A, Rogalińska M. Molecular targets of natural compounds with anti-cancer properties. Int J Mol Sci. 2021;22(24):13659,1-27.DOI: 10.3390/ijms222413659.

Lai X, Wang X, Hu Y, Su S, Li W, Li S. Editorial: network pharmacology and traditional medicine. Front Pharmacol. 2020;11:1194,1-4. DOI: 10.3389/fphar.2020.01194.

Mahboubi M. Ferula gummosa, a traditional medicine with novel applications. J Diet Suppl. 2016;13(6):700-718. DOI: 10.3109/19390211.2016.1157715.

Bahavar P, Tafrihi M. Exploring the anticancer properties of the gum of Ferula gummosa: impact on cytotoxicity, caspase 3/7 activity and apoptosis, and gene expression in SW-480 cells. Int J Environ Health Res. 2024;34(3):1810-1823.DOI: 10.1080/09603123.2023.2246403.

Nosrat T, Tabrizi MH, Etminan A, Irani M, Zarei B, Rahmati A. In vitro and in vivo anticancer activity of Ferula gummosa essential oil nanoemulsions (FGEO-NE) for the colon cancer treatment. J Polym Environ. 2022;30:4166-4177.DOI: 10.1007/s10924-022-02495-1.

Rashidi R, Roohbakhsh A, Mohtashami L, Mobasheri L, Kheradmand H, Amiri MS, et al. Cytotoxic and apoptotic effects of Ferula gummosa Boiss: extract on human breast adenocarcinoma cell line. Mol Biol Rep. 2024;51(1):592.DOI: 10.1007/s11033-024-09364-1.

Gharaei R, Akrami H, Heidari S, Asadi MH, Jalili A. The suppression effect of Ferula gummosa Boiss. extracts on cell proliferation through apoptosis induction in gastric cancer cell line. Eur J Integr Med. 2013;5(3):241-247.DOI: 10.1016/j.eujim.2013.01.002.

Wu D, Rice CM, Wang X. Cancer bioinformatics: a new approach to systems clinical medicine. BMC Bioinformatics. 2012;13:71,1-4.DOI: 10.1186/1471-2105-13-71.

Xia X. Bioinformatics and drug discovery. Curr Top Med Chem. 2017;17(15):1709-1726.DOI: 10.2174/1568026617666161116143440.

Li K, Du Y, Li L, Wei DQ. Bioinformatics approaches for anti-cancer drug discovery. Curr Drug Targets. 2020;21(1):3-17.DOI: 10.2174/1389450120666190923162203.

Ke TW, Chang SC, Yeh CM, Lin SH, Yeh KT. Comprehensive bioinformatic analysis reveals prognostic significance and functional insights of candidate gene expression in colorectal cancer. Sci Rep. 2025;15(1):5659,1-15.DOI: 10.1038/s41598-025-90025-z.

Kiran NS, Yashaswini C, Maheshwari R, Bhattacharya S, Prajapati BG. Advances in precision medicine approaches for colorectal cancer: from molecular profiling to targeted therapies. ACS Pharmacol Transl Sci. 2024;7(4):967-990.DOI: 10.1021/acsptsci.4c00008.

Mozaffarian V. Identification of medicinal and aromatic plants of Iran. 2nd ed. Tehran: Farhang Moaser Publishers; 2015.

Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, et al. ChEBI in 2016: improved services and an expanding collection of metabolites. Nucleic Acids Res. 2016;44(D1):D1214-D1219.DOI: 10.1093/nar/gkv1031.

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2023 update. Nucleic Acids Res. 2023;51(D1):D1373-D1380.DOI: 10.1093/nar/gkac956.

Omer A, Singh P. An integrated approach of network-based systems biology, molecular docking, and molecular dynamics approach to unravel the role of existing antiviral molecules against AIDS-associated cancer. J Biomol Struct Dyn.2017;35(7):1547-1558.DOI: 10.1080/07391102.2016.1188417.

Assenov Y, Ramírez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics. 2008;24(2): 282-284.DOI: 10.1093/bioinformatics/btm554.

Li S. Network pharmacology evaluation method guidance-draft. World J Tradit Chin Med. 2021;7(1):146-154.DOI: 10.4103/wjtcm.wjtcm_11_21.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235-242.DOI: 10.1093/nar/28.1.235.

UniProt Consortium. UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Res. 2023;51(D1):D523-D531.DOI: 10.1093/nar/gkac1052.

O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. J Cheminform. 2011;3: 33,1-14.DOI: 10.1186/1758-2946-3-33.

Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc. 2016;11(5):905-919.DOI: 10.1038/nprot.2016.051.

Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605-1612.DOI: 10.1002/jcc.20084.

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol. 2015;1263:243-250.DOI: 10.1007/978-1-4939-2269-7_19.

Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings. J Chem Inf Model. 2021;61(8):3891-3898.DOI: 10.1021/acs.jcim.1c00203.

Mehrab R, Sedighian H, Sotoodehnejadnematalahi F, Halabian R, Fooladi AAI. A comparative study of the arazyme-based fusion proteins with various ligands for more effective targeting cancer therapy: an in-silico analysis. Res Pharm Sci. 2023;18(2):159-176.DOI: 10.4103/1735-5362.367795.

Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: high-performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1-2:19-25. DOI: 10.1016/j.softx.2015.06.001.

Schmid N, Eichenberger AP, Choutko A, Riniker S, Winger M, Mark AE, et al. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur Biophys J. 2011;40(7):843-856.DOI: 10.1007/s00249-011-0700-9.

Mohammadi Pour P, Mahnam K, Taherzadeh M, Ahangarzadeh S, Alibakhshi A, Mohammadi E. The effect of mutation on neurotoxicity reduction of new chimeric reteplase, a computational study. Res Pharm Sci. 2023;18(4):404-412.DOI: 10.4103/1735-5362.378087.

Gharibi S, Sayed Tabatabaei BE, Saeidi G, Talebi M, Matkowski A. The effect of drought stress on polyphenolic compounds and expression of flavonoid biosynthesis-related genes in Achillea pachycephala Rech.f. Phytochemistry. 2019;162:90-98. DOI: 10.1016/j.phytochem.2019.03.004.

Shojaeian A, Mehri-Ghahfarrokhi A, Banitalebi-Dehkordi M. Increased in vitro migration of human umbilical cord mesenchymal stem cells toward acellular foreskin treated with bacterial derivatives of monophosphoryl lipid A or supernatant of Lactobacillus acidophilus. Hum cell. 2020;33(1):10-22. DOI: 10.1007/s13577-019-00308-7.

Settacomkul R, Sangpairoj K, Phuagkhaopong S, Meemon K, Niamnont N, Sobhon P, et al. Ethanolic extract of Halymenia durvillei induced G2/M arrest and altered the levels of cell cycle regulatory proteins of MDA-MB-231 triple-negative breast cancer cells. Res Pharm Sci. 2023;18(3):279-291.DOI: 10.4103/1735-5362.371584.

Shojaeian A, Mehri-Ghahfarrokhi A, Banitalebi-Dehkordi M. Migration gene expression of human umbilical cord mesenchymal stem cells: a comparison between monophosphoryl lipid A and supernatant of Lactobacillus acidophilus. Int J Mol Cell Med. 2019;8(2):154-160.DOI: 10.22088/IJMCM.BUMS.8.2.154.

Dallemole DR, Terroso T, Alves ACS, Scholl JN, Onzi GR, Cé R, et al. Nanoformulation shows cytotoxicity against glioblastoma cell lines and antiangiogenic activity in chicken chorioallantoic membrane. Pharmaceutics. 2021;13(6):862,1-20. DOI: 10.3390/pharmaceutics13060862.

Saffari-Chaleshtori J, Shojaeian A, Heidarian E, Shafiee SM. Inhibitory effects of bilirubin on colonization and migration of A431 and SK-MEL-3 skin cancer cells compared with human dermal fibroblasts (HDF). Cancer Invest. 2021;39(9): 721-733. DOI: 10.1080/07357907.2021.1943428.

Shojaeian A, Mehri-Ghahfarrokhi A, Banitalebi-Dehkordi M. Monophosphoryl lipid A and retinoic acid combinations increased germ cell differentiation markers expression in human umbilical cord-derived mesenchymal stromal cells in an in vitro ovine acellular testis scaffold. Int J Mol Cell Med. 2020;9(4):288-296.DOI: 10.22088/IJMCM.BUMS.9.4.288.

Moradzadeh M, Sadeghnia HR, Mousavi SH, Mahmoodi M, Hosseini A. Ferula gummosa gum induces apoptosis via ROS mechanism in human leukemic cells. Cell Mol Biol (Noisy-le-grand). 2017;63(11):17-22.DOI: 10.14715/cmb/2017.63.11.4.

Gudarzi H, Salimi M, Irian S, Amanzadeh A, Mostafapour Kandelous H, Azadmanesh K, et al. Ethanolic extract of Ferula gummosa is cytotoxic against cancer cells by inducing apoptosis and cell cycle arrest. Nat Prod Res. 2015;29(6):546-550.DOI: 10.1080/14786419.2014.951854.

El-Readi MZ, Al-Abd AM, Althubiti MA, Almaimani RA, Al-Amoodi HS, Ashour ML, et al. Multiple molecular mechanisms to overcome multidrug resistance in cancer by natural secondary metabolites. Front Pharmacol. 2021;12:658513,1-16.DOI: 10.3389/fphar.2021.658513.

Sheng J, Xu Z. Three decades of research on angiogenin: a review and perspective. Acta Biochim Biophys Sin (Shanghai). 2016;48(5):399-410.DOI: 10.1093/abbs/gmv131.

Wang R, Cheng L, Xia J, Wang Z, Wu Q, Wang Z. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells. Curr Cancer Drug Targets. 2014;14(4):407-417.DOI: 10.2174/1568009614666140226114015.

Ng L, Foo DCC, Wong CKH, Man ATK, Lo OSH, Law WL. Repurposing DPP-4 inhibitors for colorectal cancer: a retrospective and single-center study. Cancers (Basel). 2021;13(14):3588,1-13.DOI: 10.3390/cancers13143588.

Shah C, Hong YR, Bishnoi R, Ali A, Skelton WP 4th, Dang LH, et al. Impact of DPP4 inhibitors in survival of patients with prostate, pancreas, and breast cancer. Front Oncol. 2020;10:405,1-8.DOI: 10.3389/fonc.2020.00405.

Arcaro A. Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol. 2013;4:30,1-8.DOI: 10.3389/fphar.2013.00030.

Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429(3):403-417.DOI: 10.1042/BJ20100323.

Orlandi A, Calegari A, Inno A, Berenato R, Caporale M, Niger M, et al. BRAF in metastatic colorectal cancer: the future starts now. Pharmacogenomics. 2015;16(18):2069-2081.DOI: 10.2217/pgs.15.140.

Strouhalova K, Přechová M, Gandalovičová A, Brábek J, Gregor M, Rosel D. Vimentin intermediate filaments as potential target for cancer treatment. Cancers (Basel). 2020;12(1):184,1-20.DOI: 10.3390/cancers12010184.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.